Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

401.65INR
18 Oct 2019
Change (% chg)

Rs0.15 (+0.04%)
Prev Close
Rs401.50
Open
Rs401.00
Day's High
Rs406.50
Day's Low
Rs397.50
Volume
4,647,037
Avg. Vol
7,092,195
52-wk High
Rs616.80
52-wk Low
Rs344.55

Latest Key Developments (Source: Significant Developments)

Sun Pharma Launches Drizalma Sprinkle In U.S.
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SUN PHARMA LAUNCHES DRIZALMA SPRINKLE IN THE U.S..  Full Article

India's Sun Pharmaceutical Industries June Qtr Consol Net Profit Rises
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Sun Pharmaceutical Industries Ltd ::JUNE QUARTER CONSOL NET PROFIT 13.87 BILLION RUPEES VERSUS PROFIT OF 10.57 BILLION RUPEES LAST YEAR.JUNE QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 83.74 BILLION RUPEES VERSUS 72.24 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR JUNE QUARTER CONSOL PROFIT WAS 10.46 BILLION RUPEES.  Full Article

Sun Pharma Introduces Access Program For Patients Prescribed Xelpros In The U.S.
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Sun Pharmaceutical Industries Ltd ::SUN PHARMA INTRODUCES ACCESS PROGRAM FOR PATIENTS PRESCRIBED XELPROS IN THE U.S..SUN PHARMACEUTICAL INDUSTRIES LTD - NOW AVAILABLE AT A FIXED PRICE FROM VARIOUS PHARMACIES THROUGH XELPROS XPRESS ACCESS PROGRAM.SUN PHARMACEUTICAL - THROUGH XELPROS XPRESS, PATIENTS WITH A PRESCRIPTION CAN OBTAIN XELPROS FOR A FIXED PRICE OF $55 FOR A SINGLE MONTH.SUN PHARMACEUTICAL - THROUGH XELPROS XPRESS, PATIENTS WITH PRESCRIPTION CAN OBTAIN XELPROS FOR A PRICE OF $37 PER MONTH FOR 3-MONTH SUPPLY.  Full Article

Corcept Therapeutics says Received Paragraph IV Notice Letter Advising Sun Pharmaceutical Industries Submitted ANDA To U.S. FDA
Wednesday, 12 Jun 2019 

June 11 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING SUN PHARMACEUTICAL INDUSTRIES SUBMITTED ANDA TO U.S. FDA.CORCEPT - NOTICE LETTER ALLEGES THAT KORLYM PATENTS WILL NOT BE INFRINGED BY SUN PHARMA'S PROPOSED PRODUCT, ARE INVALID AND/OR ARE UNENFORCEABLE.CORCEPT THERAPEUTICS - ABBREVIATED NEW DRUG APPLICATION SEEKS AUTHORIZATION FROM FDA TO MANUFACTURE, USE OR SELL GENERIC VERSION OF KORLYM IN U.S..  Full Article

Sun Pharmaceutical Industries March-qtr Profit Falls
Tuesday, 28 May 2019 

May 28 (Reuters) - Sun Pharmaceutical Industries Ltd ::RECOMMENDED DIVIDEND OF 2.75 RUPEES PER SHARE.MARCH QUARTER CONSOL NET PAT 6.36 BILLION RUPEES VERSUS PROFIT OF 13.43 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 71.64 BILLION RUPEES VERSUS 69.77 BILLION RUPEES LAST YEAR.  Full Article

(OFFICIAL)-BRIEF-Taro Spokesperson Says Allegations Made In U.S. Lawsuits Without Merit (May 14)
Friday, 17 May 2019 

In May 14 Brief, corrects source in headline to say Taro spokesperson, not spokesperson of its parent Sun Pharma:BELIEVES ALLEGATIONS MADE IN U.S. LAWSUITS ARE WITHOUT MERIT, WILL CONTINUE TO "VIGOROUSLY DEFEND" AGAINST THEM.  Full Article

Sun Pharma Spokesperson Says Allegations Made In U.S. Lawsuits Are Without Merit
Tuesday, 14 May 2019 

May 14 (Reuters) - Sun Pharmaceutical Industries Spokesperson::BELIEVES ALLEGATIONS MADE IN U.S. LAWSUITS ARE WITHOUT MERIT, WILL CONTINUE TO "VIGOROUSLY DEFEND" AGAINST THEM.  Full Article

Sun Pharmaceutical Industries Says USFDA Issued Form 483 With 11 Observations Post Inspection at Dadra Facility
Friday, 26 Apr 2019 

April 26 (Reuters) - Sun Pharmaceutical Industries Ltd ::US FDA CONDUCTED AN INSPECTION OF CO.'S DADRA FACILITY FROM MARCH 22, 2019 TO MARCH 29.SUN PHARMACEUTICAL INDUSTRIES- POST INSPECTION, USFDA ISSUED A FORM 483, WITH 11 OBSERVATIONS.  Full Article

Sun Pharmaceutical Industries Launches Ready-To-Infuse Infugem In U.S
Monday, 8 Apr 2019 

April 8 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS SUN PHARMA LAUNCHES READY-TO-INFUSE INFUGEM IN THE U.S.  Full Article

Sun Pharmaceutical Industries Unit Hikes Shareholding In PJSC Biosintez
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Sun Pharmaceutical Industries Ltd ::UNIT INCREASED ITS SHAREHOLDING IN PJSC BIOSINTEZ, RUSSIA TO 96.96 PCTOF PJSC BIOSINTEZ.  Full Article